Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry
Osteoporosis International · 2025
DOI: 10.1007/s00198-025-07565-3 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Osteoporosis International, 2025. Verfasst von M J Montoya-Garcia und 21 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Medicina, Universidad de Sevilla, Hospital Universitario Virgen Macarena, Seville, Spain. Hauptthemen laut MEDLINE: Osteoporotic Fractures, Bone Density Conservation Agents, Osteoporosis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Amgen, UCB, Gedeon Richter.
Abstract (Originalsprache)
This study classifies osteoporotic patients treated in 16 FLS in Spain, evaluating therapeutic alignment with SEIOMM recommendations and imminent risk fracture. Findings indicate that 26.8% of patients are at very high-risk fracture, highlighting the need for better prescription practices for osteoanabolics. Fall prevention is pivotal in reducing new fractures. OBJECTIVE: To classify patients treated in 16 Fracture Liaison Services (FLS) in Spain according to high-risk fracture (HRF) and very high-risk fracture (VHRF) and evaluate the alignment of their pharmacological treatment with the Spanish Society for Bone and Mineral Metabolism Research (SEIOMM) guidelines. Additionally, we assessed the incidence of new fractures over a one-year follow-up period and analyzed associated risk factors. METHODS: This retrospective, multicenter, population-based observational cohort study included patients aged ≥ 50 years with at least one fragility fracture in the preceding year. Data were collected from medical records from January 2015 to April 2024, capturing sociodemographic information, fracture characteristics, comorbidities, pharmacological treatments, and fall risk. RESULTS: Of 7161 patients, 1413 had one year of follow-up and sufficient baseline data for classification as either VHRF or HRF. Among these, 1034 (73.2%) were classified as HRF and 379 (26.8%) as VHRF. The median age was significantly higher in the VHRF group (76 vs. 72 years in HRF; p < 0.001). Pharmacological treatment was initiated in 86.5% of patients. Alendronate was predominantly prescribed for the HRF group, while parenteral treatments (zoledronate, denosumab) were more common in the VHRF group. During the first year, 84 patients (5.9%) experienced a new fracture, with 2 or more falls significantly associated with these subsequent fractures. CONCLUSION: 26.8% of patients were classified as VHRF. Treatment partially aligned with SEIOMM guidelines, though improved adherence to sequential osteoanabolic treatment is essential in VHRF patients. Fall prevention remains critical to reducing fracture recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Medicina, Universidad de Sevilla, Hospital Universitario Virgen Macarena, Seville, Spain.
- Centro de Salud Via Roma ICS Barcelona, Universidad de Barcelona, Barcelona, Spain.
- Departamento de Citología E Histología Normal y Patológica, Universidad de Sevilla, Seville, Spain. mginer@us.es.
- UGC Reumatología, Hospital Universitario Virgen Macarena, Seville, Spain.
- Servicio de Reumatología, Hospital Universitari Bellvitge, Barcelona, Spain.
- Servicio de Reumatología, Hospital Universitario de Gran Canaria, Gran Canaria, Spain.
Förderung
- Amgen
- UCB
- Gedeon Richter
- Universidad de Sevilla
Zitieren
APA
Montoya-Garcia, M. J., Carbonell-Abella, C., García, M. G., Hernández-Cruz, B., Gómez-Vaquero, C., Naranjo, A., Aviñó, R. I., Miedes, D. M., Muriel, A. P. M., Mora-Fernández, J., Oreiro, S. C., Crespo, D. O., Llona, M. J., Escobar, C. A., Sureda, M. M. F., Cuadra-Llopart, L., Ramos, M. M., Zorrilla, S. S., Martínez-Laguna, D., …, & GRUPO REFRA_FLS (2025). Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry. Osteoporosis International. https://doi.org/10.1007/s00198-025-07565-3
Vancouver
Montoya-Garcia MJ, Carbonell-Abella C, García MG, Hernández-Cruz B, Gómez-Vaquero C, Naranjo A, et al. Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry. Osteoporosis International. 2025. doi:10.1007/s00198-025-07565-3
BibTeX
@article{MontoyaGarcia2025,
author = {Montoya-Garcia, M J and Carbonell-Abella, C and García, M Giner and Hernández-Cruz, B and Gómez-Vaquero, C and Naranjo, A and Aviñó, R Izquierdo and Miedes, D Mifsut and Muriel, A P Mozo and Mora-Fernández, J and Oreiro, S Castro and Crespo, D Ovejero and Llona, M Jordà and Escobar, C Alvarado and Sureda, M M Femenías and Cuadra-Llopart, L and Ramos, M Mesa and Zorrilla, S Santana and Martínez-Laguna, D and Díaz-Guerra, G Martínez and Cancio-Trujillo, J M and GRUPO REFRA_FLS, GRUPO REFRA_FLS},
title = {Adequacy of pharmacological prescription in patients at very high risk of fracture within the FLS in Spain: analysis of the REFRA FLS-SEIOMM Registry},
journal = {Osteoporosis International},
year = {2025},
doi = {10.1007/s00198-025-07565-3}
}
EUVIMED